Lacto-N-tetraose [14116-68-8]
Référence T65265-10mg
Conditionnement : 10mg
Marque : TargetMol
Contactez votre distributeur local :
Téléphone : +1 850 650 7790
Lacto-N-tetraose
Copy Product Info
Lacto-N-tetraose is a core component of human milk oligosaccharides (HMOs) and is a tetrasaccharide composed of galactose, N-acetylglucosamine, and glucose. Lacto-N-tetraose exhibits a variety of biological activities, including prebiotic effects, immunomodulatory effects, anti-inflammatory effects, regulation of intestinal cell responses, as well as antibacterial and antiviral activities. Lacto-N-tetraose is widely used in infant formula, functional foods, and biomedical research.
Cas No. 14116-68-8
For research use only—not for human use. No sales to individuals. Use as intended only.
Select Batch
Purity:99.96%
Appearance:Solid
Color:White
COA LCMS HNMR
Product Introduction
Bioactivity
Chemical Properties
Storage & Solubility Information
| Description | Lacto-N-tetraose is a core component of human milk oligosaccharides (HMOs) and is a tetrasaccharide composed of galactose, N-acetylglucosamine, and glucose. Lacto-N-tetraose exhibits a variety of biological activities, including prebiotic effects, immunomodulatory effects, anti-inflammatory effects, regulation of intestinal cell responses, as well as antibacterial and antiviral activities. Lacto-N-tetraose is widely used in infant formula, functional foods, and biomedical research. |
| In vitro | Methods: Human peripheral blood lymphocytes (HPBL) were treated with Lacto-N-tetraose (250, 500, 1,000, 2,000 μg/mL) for 3 or 20 hours. Cytoplasmic fragmentation was assessed, and the CBPI and micronucleus rate were calculated. Results: Lacto-N-tetraose did not induce chromosomal breaks or aneuploidy. [1] |
| In vivo | Methods: Neonatal Sprague-Dawley rats were administered Lacto-N-tetraose (1,000, 2,500, 4,000 mg/kg/day) orally via gavage once daily starting at PND 7 for 90 days. Results: No adverse effects were observed at the highest dose of Lacto-N-tetraose (4,000 mg/kg/day), which was the maximum tolerated dose. [1] Methods: A constipation model was established in female BALB/c mice by intraperitoneal injection of loperamide (10 mg/kg), followed by oral gavage of Lacto-N-tetraose (450 mg/kg) once daily for 14 days. Results: Lacto-N-tetraose effectively improved gastrointestinal motility and bowel movements. [2] |
| Molecular Weight | 707.63 |
| Formula | C26H45NO21 |
| Cas No. | 14116-68-8 |
| Smiles | O([C@H]1[C@H](NC(C)=O)[C@@H](O[C@@H]2O[C@H](CO)[C@H](O)[C@H](O)[C@H]2O)[C@H](O)[C@@H](CO)O1)[C@@H]3[C@@H](O)[C@H](O[C@@H]([C@@H]([C@H](C=O)O)O)[C@@H](CO)O)O[C@H](CO)[C@@H]3O |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 80.00 mg/mL (113.05 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
Note : The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density. | ||||||||||||||||||||||||||||||||||||